Effect of Antiretroviral Therapy and Viral Load on the Perceived Risk of HIV Transmission and the Need for Safer Sexual Practices
- 1 October 1998
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 19 (2), 124-129
- https://doi.org/10.1097/00042560-199810010-00004
Abstract
Dramatic reductions in plasma HIV RNA levels are possible with current antiretroviral regimens; the effect of potent therapies and “undetectable” viral load on the perceived risk of HIV transmission and need for safer practices remains unknown. A questionnaire was developed to examine perceptions of HIV transmission risk and need for safer practices with unprotected anal, vaginal, and oral sex and intravenous drug use with needle sharing for HIV-discordant couples in which the HIV-infected partner was receiving no therapy, was receiving reverse transcriptase inhibitor therapy, and protease inhibitor (PI)-based therapy with viral load “undetectable”. This was applied anonymously to 147 unselected HIV-infected individuals attending a university-based HIV clinic. Almost all respondents believed that all sexual activities except oral sex were “very risky” and that safer practices were “extremely important” for those not receiving antiretroviral agents. Significantly fewer considered that anal or vaginal sex was “very risky” for those receiving PI therapy (90.9% and 86.0%, respectively), and fewer thought that safer practices for anal or vaginal sex were “very important” for those receiving PI therapy (93.0% and 91.6%, respectively). In total, 20.4% thought the risk of HIV transmission for at least one activity was reduced for those receiving PI therapy, and 19.0% believed that the need for safer practices was reduced by PI therapy. A small but significant proportion of HIV-infected people perceive the need for safer practices to be reduced during antiretroviral therapy, particularly those containing PIs. Even if the risk is truly reduced, the importance of safer practices should be conveyed consistently and terms such as “undetectable” to describe HIV RNA responses should be avoided.Keywords
This publication has 8 references indexed in Scilit:
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Are Advances in Treatment Changing Views about High-Risk Sex?New England Journal of Medicine, 1997
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine TreatmentNew England Journal of Medicine, 1994
- Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual TransmissionArchives of Internal Medicine, 1994
- Detection of Human Immunodeficiency Virus Type 1 in Semen: Effects of Disease Stage and Nucleoside TherapyThe Journal of Infectious Diseases, 1993
- Recovery of Human Immunodeficiency Virus Type 1 from Semen: Minimal Impact of Stage of Infection and Current Antiviral ChemotherapyThe Journal of Infectious Diseases, 1991
- HIV seroconversion in two homosexual men after receptive oral intercourse with ejaculation: implications for counseling concerning safe sexual practices.American Journal of Public Health, 1990
- Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complexJAMA, 1988